Recently, Jain et al. have disrupted the effects of the mutant myocilin gene using AAV-CRISP/Cas9 in a mouse model of myocilin-associated glaucoma and were able to lower IOP and prevent further glaucomatous damage [131]. This evidence concerns the gene MYOC and glaucoma.